Hexacath - Medical company leader in Bio Active coronary Stent

Clinical Excellence in ACS treatment

Evidence Based Medicine

Technologies Driven by Innovation

Patient’s Course Made Easier & Safer

+ 500

million

people around the world are affected by cardiovascular diseases (CVD) every year

Source: WHR 2023

20,5

million

people died from CVDs in 2021 (an estimated)

1/3

of all global deaths

cardiovascular diseases accounted for close to a third of all global deaths

85%

of these deaths

were due to heart attack and stroke

Healthcare Professionals

Clinical Excellence

Prix Galien

Hexacath France received the Prix Galien 2021 in the “Medical Device” category with TiTAN OPTiMAX indicated in the treatment of coronary syndromes

More details

Pre-Clinical
Experience

Before committing to the development of new technologies, Hexacath relied on a large body of pre-clinical evidence and fundamental in vitro and in vivo studies.

More details

Clinical Evidence

Over almost 2 decades have been necessary to gather an impressive amount of clinical evidence demonstrating the Titan bioactive stent Superiority in ACS drug-eluting stent in Acute Coronary Syndrome patients and the interest of the continuous thermodilution technology using the RayFlow microcatheter to assess Coronary Microvascular Disease.

More details